Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
2.750
-0.170 (-5.82%)
At close: Jun 5, 2026, 4:00 PM EDT
2.785
+0.035 (1.27%)
After-hours: Jun 5, 2026, 7:43 PM EDT
Rocket Pharmaceuticals Employees
Rocket Pharmaceuticals had 202 employees as of December 31, 2025. The number of employees decreased by 97 or -32.44% compared to the previous year.
Employees
202
Change (1Y)
-97
Growth (1Y)
-32.44%
Revenue / Employee
n/a
Profits / Employee
-$1,036,550
Market Cap
300.28M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 202 | -97 | -32.44% |
| Dec 31, 2024 | 299 | 31 | 11.57% |
| Dec 31, 2023 | 268 | 28 | 11.67% |
| Dec 31, 2022 | 240 | 89 | 58.94% |
| Dec 31, 2021 | 151 | 60 | 65.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Abeona Therapeutics | 226 |
| Humacyte | 184 |
| Nautilus Biotechnology | 127 |
| Invivyd | 122 |
| Neumora Therapeutics | 96 |
| Silence Therapeutics | 88 |
| Lineage Cell Therapeutics | 77 |
RCKT News
- 2 days ago - Rocket Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 3 days ago - Rocket Pharmaceuticals price target raised to $10 from $9 at BofA - TheFly
- 17 days ago - Rocket Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c) - TheFly
- 4 weeks ago - Rocket Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Rocket Pharmaceuticals Earnings release: Q1 2026 - Filings
- 5 weeks ago - Rocket Pharmaceuticals announces $180M sale of priority review voucher - TheFly
- 2 months ago - Rocket Pharmaceuticals Proxy statement: Proxy filing - Filings